108 related articles for article (PubMed ID: 32064677)
21. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma.
Kim TY; Kim WB; Song JY; Rhee YS; Gong G; Cho YM; Kim SY; Kim SC; Hong SJ; Shong YK
Clin Endocrinol (Oxf); 2005 Nov; 63(5):588-93. PubMed ID: 16268813
[TBL] [Abstract][Full Text] [Related]
22. A rare case of BRAF V600E-mutated epithelioid glioblastoma with a sarcomatous component.
Ishikawa R; Kadota K; Hayashi T; Kimura N; Inoue K; Ibuki E; Kagawa S; Kushida Y; Okada M; Miyake K; Tamiya T; Nobusawa S; Hirato J; Haba R
Pathol Int; 2020 Mar; 70(3):166-170. PubMed ID: 31903645
[TBL] [Abstract][Full Text] [Related]
23. Frequent PIK3CA activating mutations in nipple adenomas.
Liau JY; Lee YH; Tsai JH; Yuan CT; Chu CY; Hong JB; Sheen YS
Histopathology; 2017 Jan; 70(2):195-202. PubMed ID: 27441415
[TBL] [Abstract][Full Text] [Related]
24. Metanephric adenoma with BRAF V600K mutation and a doubtful radiological imaging: pitfalls in the diagnostic process.
Lenci N; Francesco P; Scarciglia E; Fiorentino V; Schino M; Palermo G; Racioppi M; Bassi P; Martini M
Med Mol Morphol; 2021 Jun; 54(2):187-191. PubMed ID: 33175195
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical staining for BRAF V600E supports the diagnosis of metanephric adenoma.
Pinto A; Signoretti S; Hirsch MS; Barletta JA
Histopathology; 2015 May; 66(6):901-4. PubMed ID: 25130952
[No Abstract] [Full Text] [Related]
26. Reappraisal of the genetic heterogeneity of sessile serrated adenoma/polyp.
Cho H; Hashimoto T; Yoshida H; Taniguchi H; Ogawa R; Mori T; Hiraoka N; Saito Y; Sekine S
Histopathology; 2018 Oct; 73(4):672-680. PubMed ID: 29920740
[TBL] [Abstract][Full Text] [Related]
27. BRAF V600E immunohistochemistry demonstrates that some sessile serrated lesions with adenomatous dysplasia may represent collision lesions.
Bettington M; Liu C; Gill A; Walker N; Leggett B; Whitehall V; Rosty C
Histopathology; 2019 Jul; 75(1):81-87. PubMed ID: 30825335
[TBL] [Abstract][Full Text] [Related]
28. Identification of somatic TERT promoter mutations in familial nonmedullary thyroid carcinomas.
Marques IJ; Moura MM; Cabrera R; Pinto AE; Simões-Pereira J; Santos C; Menezes FD; Montezuma D; Henrique R; Rodrigues Teixeira M; Leite V; Cavaco BM
Clin Endocrinol (Oxf); 2017 Oct; 87(4):394-399. PubMed ID: 28502101
[TBL] [Abstract][Full Text] [Related]
29. Massively parallel sequencing analysis of benign melanocytic naevi.
Lozada JR; Geyer FC; Selenica P; Brown D; Alemar B; Merghoub T; Berger MF; Busam KJ; Halpern AC; Weigelt B; Reis-Filho JS; Hollmann TJ
Histopathology; 2019 Jul; 75(1):29-38. PubMed ID: 30791119
[TBL] [Abstract][Full Text] [Related]
30. MLH1-deficient Colorectal Carcinoma With Wild-type BRAF and MLH1 Promoter Hypermethylation Harbor KRAS Mutations and Arise From Conventional Adenomas.
Farchoukh L; Kuan SF; Dudley B; Brand R; Nikiforova M; Pai RK
Am J Surg Pathol; 2016 Oct; 40(10):1390-9. PubMed ID: 27438990
[TBL] [Abstract][Full Text] [Related]
31. Clinical utility of EZH1 mutations in the diagnosis of follicular-patterned thyroid tumors.
Jung CK; Kim Y; Jeon S; Jo K; Lee S; Bae JS
Hum Pathol; 2018 Nov; 81():9-17. PubMed ID: 29723601
[TBL] [Abstract][Full Text] [Related]
32. Serrated and non-serrated polyps of the colorectum: their prevalence in an unselected case series and correlation of BRAF mutation analysis with the diagnosis of sessile serrated adenoma.
Carr NJ; Mahajan H; Tan KL; Hawkins NJ; Ward RL
J Clin Pathol; 2009 Jun; 62(6):516-8. PubMed ID: 19126563
[TBL] [Abstract][Full Text] [Related]
33. [BRAF mutation in colorectal serrated lesions].
Zhou ZY; Han Y; Wang LP
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3411-4. PubMed ID: 19159571
[TBL] [Abstract][Full Text] [Related]
34. BRAF and KRAS mutations in tubular apocrine adenoma and papillary eccrine adenoma of the skin.
Liau JY; Tsai JH; Huang WC; Lan J; Hong JB; Yuan CT
Hum Pathol; 2018 Mar; 73():59-65. PubMed ID: 29241739
[TBL] [Abstract][Full Text] [Related]
35. Microfluidic-Based Immunohistochemistry Combined With Next-Generation Sequencing on Diagnostic Tissue Sections for Detection of Tumoral BRAF V600E Mutation.
Leblond AL; Rechsteiner M; Jones A; Brajkovic S; Dupouy D; Soltermann A
Am J Clin Pathol; 2019 Jun; 152(1):59-73. PubMed ID: 31065676
[TBL] [Abstract][Full Text] [Related]
36. Metanephric stromal tumor in an adult with PDGFRA mutation: a case report.
Guo S; Qian H; Zhu H; Yang Y; Yang X; Sun H
Diagn Pathol; 2023 Jul; 18(1):83. PubMed ID: 37454137
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of EZH2 expression, BRAF V600E mutation, and CDKN2A/B deletions in epithelioid glioblastoma and anaplastic pleomorphic xanthoastrocytoma.
Wang J; Liu Z; Cui Y; Liu Y; Fang J; Xu L; He Y; Du J; Su Y; Zou W; Xu Z; Li G
J Neurooncol; 2019 Aug; 144(1):137-146. PubMed ID: 31214915
[TBL] [Abstract][Full Text] [Related]
38. The genetic landscape of ganglioglioma.
Pekmezci M; Villanueva-Meyer JE; Goode B; Van Ziffle J; Onodera C; Grenert JP; Bastian BC; Chamyan G; Maher OM; Khatib Z; Kleinschmidt-DeMasters BK; Samuel D; Mueller S; Banerjee A; Clarke JL; Cooney T; Torkildson J; Gupta N; Theodosopoulos P; Chang EF; Berger M; Bollen AW; Perry A; Tihan T; Solomon DA
Acta Neuropathol Commun; 2018 Jun; 6(1):47. PubMed ID: 29880043
[TBL] [Abstract][Full Text] [Related]
39. BRAF alterations are associated with complex mutational profiles in malignant melanoma.
Daniotti M; Oggionni M; Ranzani T; Vallacchi V; Campi V; Di Stasi D; Torre GD; Perrone F; Luoni C; Suardi S; Frattini M; Pilotti S; Anichini A; Tragni G; Parmiani G; Pierotti MA; Rodolfo M
Oncogene; 2004 Aug; 23(35):5968-77. PubMed ID: 15195137
[TBL] [Abstract][Full Text] [Related]
40. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
